Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer

Inclusion Criteria: * loco-regionally recurrent NSCLC after thoracic radiotherapy (confirmed by pathology or continuous enhanced CT imaging); * chemotherapy, targeted or immunotherapy are allowed before enrollment; * \>=6 months from previous chest radiotherapy; * presence of measurable disease according to RECIST criteria; * ECOG performance score is 0-1; * organ and bone marrow functions meet the following criteria: * forced expiratory volume in 1 second (FEV1) ≥ 0.8L; * percentage-predicted single-breath carbon monoxide diffusing capacity (DLCO %) \> 60%; * absolute neutrophil count ≥1.5×10\^9/L; * platelet ≥80×10\^9/L; * hemoglobin ≥9.0g/dL; * serum creatinine clearance was ≥50 mL/min calculated based on the Cockcroft-Gault formula * serum bilirubin ≤1.5 times normal upper limit (ULN) * AST and ALT≤2.5 times ULN Exclusion Criteria: * previous or concurrent with other malignant tumors, except for non-melanoma of the skin or carcinoma in situ of the cervix; * loco-regional recurrence with distant metastasis; * any other disease or condition contradicted to radiotherapy (e.g., active infection, within 6 months after myocardial infarction, symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia, immunosuppressive therapy); * women who are pregnant or breastfeeding, women who have not undergone a pregnancy test (within 14 days before first administration), and women who are pregnant; * pregnancy, lactation, or fertility but no contraceptive measures; * those with bleeding tendency; * participate in other clinical trials within 30 days before enrollment; * drug and other drug addiction, chronic alcoholism and AIDS patients; * having uncontrollable seizures or loss of self-control due to psychosis; * a history of severe allergies; * participants considered unfit to participate in this study.